- Home
- JLL vs INCY Comparison
JLL vs INCY Comparison
Compare JLL & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JLL | INCY |
|---|---|---|
| Founded | 1997 | 1991 |
| Country | United States | United States |
| Employees | 48000 | N/A |
| Industry | Real Estate | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.3B | 17.0B |
| IPO Year | 1997 | 1994 |
Fundamental Metrics
Financial Performance| Metric | JLL | INCY |
|---|---|---|
| Price | $382.55 | $127.49 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 21 |
| Target Price | ★ $365.33 | $103.52 |
| AVG Volume (30 Days) | 335.7K | ★ 1.5M |
| Earning Date | 04-30-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 45.13 | ★ 4173.33 |
| EPS | ★ 7.91 | 1.47 |
| Revenue | ★ $26,115,600,000.00 | $3,394,635,000.00 |
| Revenue This Year | $7.71 | $10.44 |
| Revenue Next Year | $6.99 | $10.99 |
| P/E Ratio | ★ $48.81 | $87.16 |
| Revenue Growth | 11.45 | ★ 13.67 |
| 52 Week Low | $259.83 | $81.09 |
| 52 Week High | $393.84 | $132.60 |
Technical Indicators
Market Signals| Indicator | JLL | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 63.50 | 60.23 |
| Support Level | $313.99 | $98.50 |
| Resistance Level | $393.84 | $132.60 |
| Average True Range (ATR) | 9.19 | 2.81 |
| MACD | -0.09 | 0.20 |
| Stochastic Oscillator | 76.44 | 71.00 |
Price Performance
Historical ComparisonAbout JLL Jones Lang LaSalle Incorporated
Jones Lang LaSalle is a global commercial real estate services and investment management company that helps clients buy, build, occupy, manage, and invest in property across office, industrial, retail, multifamily, hotel, and data center assets. For over 200 years, clients have trusted JLL, a Fortune 500 company, tracing its roots to firms including LaSalle Partners (founded in Chicago in 1968) and the centuries-old London firm Jones Lang Wootton, which merged in 1999 to form the modern JLL. Today the firm is a leading global commercial real estate services and investment management company with operations in over 80 countries, and a global workforce of more than 113,000, as of early 2026.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.